KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) EBITDA: 2017-2024

Historic EBITDA for Adaptive Biotechnologies (ADPT) over the last 8 years, with Dec 2024 value amounting to -$162.5 million.

  • Adaptive Biotechnologies' EBITDA rose 171.96% to $10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$60.8 million, marking a year-over-year increase of 53.90%. This contributed to the annual value of -$162.5 million for FY2024, which is 28.40% up from last year.
  • Latest data reveals that Adaptive Biotechnologies reported EBITDA of -$162.5 million as of FY2024, which was up 28.40% from -$227.0 million recorded in FY2023.
  • Over the past 5 years, Adaptive Biotechnologies' EBITDA peaked at -$152.8 million during FY2020, and registered a low of -$227.0 million during FY2023.
  • Over the past 3 years, Adaptive Biotechnologies' median EBITDA value was -$200.2 million (recorded in 2022), while the average stood at -$196.6 million.
  • Per our database at Business Quant, Adaptive Biotechnologies' EBITDA plummeted by 94.94% in 2020 and then climbed by 28.40% in 2024.
  • Yearly analysis of 5 years shows Adaptive Biotechnologies' EBITDA stood at -$152.8 million in 2020, then tumbled by 36.74% to -$209.0 million in 2021, then increased by 4.20% to -$200.2 million in 2022, then declined by 13.41% to -$227.0 million in 2023, then grew by 28.40% to -$162.5 million in 2024.